Skip to content
Screener

Trimas TRS Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Kulicke & Soffa Industries logo
Kulicke & Soffa IndustriesKLIC
$5M0.0%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$168.3M+10.4%
Gross profit$36.9M+12.3%
Operating income$6.9M-3.6%
Net income$800.8M+6,348%
EPS (diluted)$21.40+7,033%

Balance sheet

See full
Cash & equivalents$1.3B+3,904%
Total debt$439.9M-9.2%
Total equity$1.4B+111%
Total assets$2.3B+64.8%

Cash flow

See full
Operating cash flow-$19.4M-311%
CapEx$5.2M-59.7%
Free cash flow-$24.6M-556%

Valuation

See full
Market cap$1.43B+1.4%
Enterprise value$565.19M-69.6%
P/E1.6×-36.4×
P/S2.2×-0.1×

Profitability

See full
Gross margin-0.1%-2.1pp
Operating margin8%-1.0pp
Net margin137.3%+132pp
FCF margin7.3%+3.1pp

Returns & leverage

See full
Return on equity85.1%+80.4pp
Debt / equity0.3×-0.4×
Current ratio4.9×+2.0×

Where this comes from

Reported directly by Trimas in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: Trimas’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 1:53 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000842633-26-000029
AssetsMarch 31,2026 / (unaudited)December 31,2025
Other long-term liabilities61,49065,840
Non-current liabilities, discontinued operations11,290
Total liabilities847,320779,490
Preferred stock, $0.01 par: Authorized 100,000,000 shares; Issued and outstanding: None
Common stock, $0.01 par: Authorized 400,000,000 shares;Issued and outstanding: 36,336,668 shares at March 31, 2026 and 37,630,206 shares at December 31, 2025360380
Paid-in capital532,540577,810
Retained earnings917,120127,410
Accumulated other comprehensive income (loss)(210)(10)

Item 1. Consolidated Financial Statements

FAQ

What is Trimas's preferred stock, shares authorized?
Trimas (TRS) reported preferred stock, shares authorized of $100M in Q1 2026.
How has Trimas's preferred stock, shares authorized changed year-over-year?
Trimas's preferred stock, shares authorized decreased by 0.0% year-over-year, from $100M to $100M.
What is the long-term trend for Trimas's preferred stock, shares authorized?
Over 5 years (2020 to 2025), Trimas's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $100M to $100M.

Ask your AI about Trimas's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude